AMIKACIN SULFATE INJECTION, 500 MG/2ML injection United States - English - NLM (National Library of Medicine)

amikacin sulfate injection, 500 mg/2ml injection

safrel pharmaceuticals, llc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) -

ERFA-AMIKACIN SOLUTION Canada - English - Health Canada

erfa-amikacin solution

searchlight pharma inc - amikacin (amikacin sulfate) - solution - 250mg - amikacin (amikacin sulfate) 250mg - aminoglycosides

HOSPIRA AMIKACIN INJECTION amikacin (as sulfate) 500mg/2mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

hospira amikacin injection amikacin (as sulfate) 500mg/2ml solution for injection vial

hospira australia pty ltd - amikacin -

Amikacine B. Braun 2,5 mg/ml inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine b. braun 2,5 mg/ml inf. sol. i.v.

b. braun melsungen ag - amikacin sulfate 3,34 mg/ml - eq. amikacin 2,5 mg/ml - solution for infusion - 2,5 mg/ml - amikacin sulfate 3.34 mg/ml - amikacin

Amikacine B. Braun 5 mg/ml inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine b. braun 5 mg/ml inf. sol. i.v.

b. braun melsungen ag - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin

Amikacine B. Braun 10 mg/ml inf. sol. i.v. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine b. braun 10 mg/ml inf. sol. i.v.

b. braun melsungen ag - amikacin sulfate 13,35 mg/ml - eq. amikacin 10 mg/ml - solution for infusion - 10 mg/ml - amikacin sulfate 13.35 mg/ml - amikacin

Amikacine Fresenius Kabi 5 mg/ml inf. sol. i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine fresenius kabi 5 mg/ml inf. sol. i.v. vial

fresenius kabi sa-nv - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin

Amikacine Fresenius Kabi 5 mg/ml inf. sol. i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine fresenius kabi 5 mg/ml inf. sol. i.v. vial

fresenius kabi sa-nv - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin

Amikacine Fresenius Kabi 5 mg/ml inf. sol. i.v. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amikacine fresenius kabi 5 mg/ml inf. sol. i.v. vial

fresenius kabi sa-nv - amikacin sulfate 6,68 mg/ml - eq. amikacin 5 mg/ml - solution for infusion - 5 mg/ml - amikacin sulfate 6.68 mg/ml - amikacin

AMIWOK amikacin (as sulfate) 500mg/2mL solution for injection infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

amiwok amikacin (as sulfate) 500mg/2ml solution for injection infusion vial

wockhardt bio pty ltd - amikacin sulfate, quantity: 333.76 mg/ml (equivalent: amikacin, qty 250 mg/ml) - injection, solution - excipient ingredients: sodium citrate; water for injections; sulfuric acid; sodium metabisulfite - amiwok is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see microbiology).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics.,amiwok is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post- operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.